3058-61-5Relevant academic research and scientific papers
Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer
Ning, Wentao,Hu, Zhiye,Tang, Chu,Yang, Lu,Zhang, Silong,Dong, Chune,Huang, Jian,Zhou, Hai-Bing
supporting information, p. 8155 - 8173 (2018/08/09)
In this work, we developed a small library of novel OBHS-RES hybrid compounds with dual inhibition activities targeting both the estrogen receptor α (ERα) and NF-?B by incorporating resveratrol (RES), a known inhibitor of NF-?B, into a privileged indirect antagonism structural motif (OBHS, oxabicycloheptene sulfonate) of estrogen receptor (ER). The OBHS-RES conjugates could bind well to ER and showed remarkable ERα antagonistic activity, and they also exhibited excellent NO inhibition in macrophage RAW 264.7 cells. Compared with 4-hydroxytamoxifen, some of them showed better antiproliferative efficacy in MCF-7 cell lines with IC50 up to 3.7 μM. In vivo experiments in a MCF-7 breast cancer model in Balb/c nude mice indicated that compound 26a was more potent than tamoxifen. Exploration of the compliancy of the structure against ER specificity utilizing these types of isomeric three-dimensional ligands indicated that one enantiomer had much better biological activity than the other.
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
Tang, Chu,Li, Changhao,Zhang, Silong,Hu, Zhiye,Wu, Jun,Dong, Chune,Huang, Jian,Zhou, Hai-Bing
supporting information, p. 4550 - 4572 (2015/06/25)
A strategy to develop chemotherapeutic agents by combining several active groups into a single molecule as a conjugate that can modulate multiple cellular pathways may produce compounds having higher efficacy compared to that of single-target drugs. In th
